Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status. It is grouped under the following drug class(es): CT contrast agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Urokonic acid, Acetrizoate, Opacaron and Urokon. Its PubChem CID is 6806.
Acetrizoic acid
| CAS No | 85-36-9 |
|---|---|
| Molecular Formula | C9H6I3NO3 |
| Molecular Weight | 556.86 g/mol |
| Synonyms | 3-acetamido-2,4,6-triiodobenzoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent.
The listed CAS number is 85-36-9.
The listed molecular formula is C9H6I3NO3.
The listed molecular weight is 556.86 g/mol.
3-acetamido-2,4,6-triiodobenzoic acid.
The source lists Urokonic acid, Acetrizoate, Opacaron and Urokon.